Andere Kunden interessierten sich auch für
![Regulatory Guidelines for Registration and Submission Criteria in South Africa (SAHPRA)]( "Regulatory Guidelines for Registration and Submission Criteria in South Africa (SAHPRA)")
Regulatory Guidelines for Registration and Submission Criteria in South Africa (SAHPRA)47,95 €![Method Validation and Stability Analysis of Rifampicin by LC and LC-MS]( "Method Validation and Stability Analysis of Rifampicin by LC and LC-MS")
Method Validation and Stability Analysis of Rifampicin by LC and LC-MS40,99 €![Purification and Fractionation Strategies for Natural Products]( "Purification and Fractionation Strategies for Natural Products")
Purification and Fractionation Strategies for Natural Products45,99 €![Developing a Health Sector National Supply Chain Strategy]( "Developing a Health Sector National Supply Chain Strategy")
Developing a Health Sector National Supply Chain Strategy27,99 €![Mathematical Aspects & IVIVC Development of Extended Release Products]( "Mathematical Aspects & IVIVC Development of Extended Release Products")
Mathematical Aspects & IVIVC Development of Extended Release Products27,99 €![Computational study on natural products as emerging hope for arthritis]( "Computational study on natural products as emerging hope for arthritis")
Computational study on natural products as emerging hope for arthritis24,99 €![Comparison of a global submission of new biological or chemical entity]( "Comparison of a global submission of new biological or chemical entity")
Comparison of a global submission of new biological or chemical entity59,99 €
Brexit has significantly reshaped pharmaceutical product submissions by separating the UK from the EU's centralized regulatory framework. Before Brexit, the European Medicines Agency (EMA) oversaw marketing authorizations, ensuring harmonized access across member states. Now, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) independently regulates medicines, requiring separate applications for UK and EU markets. This has led to duplication of dossiers, increased costs, and potential delays in patient access to innovative medicines. The loss of EU funding, research collaborations, and access to databases like EudraVigilance has also impacted innovation, pharmacovigilance, and clinical trials. New UK systems, including UKCA marking and national submission routes, aim to fill gaps but challenge smaller companies. While Brexit introduces complexity and uncertainty, it also offers the UK opportunities to develop flexible, faster approval pathways and strengthen its position as a research hub, provided collaboration and investment continue.